Event Date/Time: May 23, 2005
End Date/Time: May 25, 2005
Most researchers working in drug and diagnostic development agree that when it comes to biomarker research, “cancer is the outlier.” This may be due to the fact that cancer is such a heterogeneous disease and can benefit most from personalized medicine approaches. It is also an area where early, pre-symptomatic diagnosis dramatically improves the odds of successful treatment. And because it is one of the leading causes of death, significant government and industry resources have been invested in cancer research. Whatever the reason may be, biomarker research in cancer diagnosis and drug development is years ahead of other indication areas. In May 2004, over 300 researchers and clinicians gathered in Philadelphia at the Inaugural Cancer Biomarkers meeting. In 2005, we are returning to Philly for a status update on this rapidly-developing field. By co-locating the meeting with The Biomarker World Congress, we also offer access to 4 focused tracks, exhibit and poster viewing, and all networking offered by an international event.